Cancer Biomarker Testing Guide: CEA, CA-125, PSA, CTC — What Patients Need to Know (2026)
By The Medical Advisor Editorial Team | Originally published June 2026 | Updated August 2026 | Medically reviewed and fact-checked against 2026 guideline updates from AUA/SUO, ACS, and ASCO
Disclosure: Some links in this article may be affiliate links, including The Wellness Company (referral code ONEDAYMD) and Amazon Associates. If you purchase through these links, we may earn a commission at no extra cost to you. This does not influence our evidence grading or editorial conclusions.
Quick Answer
Cancer biomarkers are measurable substances in blood or tissue that signal the possible presence, progression, or recurrence of cancer — they are tools that raise or lower suspicion, not diagnoses. CEA is used mainly to monitor colorectal cancer after treatment; CA-125 monitors epithelial ovarian cancer and works best alongside HE4 and ultrasound; PSA screens for and monitors prostate cancer but requires nuanced, age- and risk-adjusted interpretation; and CTC (circulating tumour cells) is a "liquid biopsy" prognostic marker validated for metastatic breast, colorectal, and prostate cancer. None of the four is validated as a stand-alone general-population screening test, and single readings matter less than the trend over time. As of 2026, guideline bodies (AUA/SUO, ACS, ASCO) have updated key recommendations affecting how several of these tests are used — details below.
Biomarker tests are tools, not diagnoses. Elevated levels require clinical correlation and further investigation. This guide is for educational purposes and does not constitute medical advice.
.png)
On this page
What Are Cancer Biomarkers?
A cancer biomarker is a biological molecule found in blood, tissues, or other body fluids that is produced either by a tumour or by the body in response to a tumour. The ideal biomarker would be:
- Specific — elevated only in the presence of cancer, not benign conditions
- Sensitive — detectable even at early disease stages
- Prognostic — able to predict disease course
- Actionable — its level guides treatment decisions
In practice, no current biomarker perfectly meets all four criteria. Each has known limitations, and results must always be interpreted in clinical context.
Types of biomarkers
Protein biomarkers are the most commonly used in clinical practice — CEA, CA-125, and PSA all fall into this category. They are secreted by tumour cells or surrounding tissue and measured in the blood.
Cellular biomarkers include circulating tumour cells (CTCs), which are intact cancer cells shed from a primary tumour into the bloodstream. CTC testing represents a form of "liquid biopsy."
Genetic/molecular biomarkers include circulating tumour DNA (ctDNA), mutations (e.g. BRCA1/2, KRAS, EGFR), and methylation patterns. These are increasingly used in precision oncology and are covered in depth in our companion guides on ctDNA testing and multi-cancer early detection.
CEA — Carcinoembryonic Antigen
What is CEA?
CEA is a glycoprotein normally produced during foetal development. In healthy adults, blood levels are very low. It was first described in 1965 by Gold and Freedman as a marker of colorectal cancer.
What cancers is CEA used for?
CEA is most commonly elevated in:
- Colorectal cancer (most validated use)
- Lung cancer (non-small cell)
- Breast cancer
- Pancreatic cancer
- Gastric (stomach) cancer
- Thyroid cancer (medullary type)
- Ovarian cancer
Normal reference ranges
| Population | Normal CEA |
|---|---|
| Non-smokers | < 2.5 ng/mL |
| Smokers | < 5.0 ng/mL |
| Mild elevation (non-specific) | 5–10 ng/mL |
| Suspicious for malignancy | > 10 ng/mL |
| Advanced/metastatic disease | Often > 20 ng/mL |
Note: Reference ranges may vary slightly between laboratories. Always interpret against your lab's own reference interval.
Non-cancerous causes of elevated CEA
CEA is not cancer-specific. It can be elevated in:
- Smoking — even moderate smoking raises baseline CEA
- Liver disease (cirrhosis, hepatitis)
- Inflammatory bowel disease (Crohn's, ulcerative colitis)
- Peptic ulcer disease
- Pancreatitis
- Hypothyroidism
- Chronic obstructive pulmonary disease (COPD)
- Benign breast disease
- Pregnancy
This is why CEA is not recommended as a screening tool for cancer in asymptomatic people — the false-positive rate is high.
📌 Don't confuse CEA with the new CRC "blood test" in the news
On May 27, 2026, the American Cancer Society updated its colorectal cancer screening guideline for the first time since 2018 — adding a blood-based ctDNA test (brand name Shield, Guardant Health) as a non-preferred screening option for average-risk adults who decline colonoscopy or stool-based testing, alongside a new stool mt-sRNA test (ColoSense). This is a different tool from CEA: Shield is a primary screening test for people without a diagnosis, while CEA is a monitoring marker used after colorectal cancer has already been diagnosed and treated. Shield showed lower sensitivity for advanced precancerous lesions and Stage I cancers than colonoscopy or stool-based tests, and any positive result still requires a follow-up colonoscopy.
How CEA is used clinically
Monitoring treatment response: CEA is most valuable for patients already diagnosed with colorectal cancer. A falling CEA during chemotherapy or after surgery suggests effective treatment. A rising CEA after remission raises concern for recurrence.
Detecting recurrence: After curative resection of colorectal cancer, CEA is monitored every 3–6 months for the first 2 years, then annually. A sustained rise prompts imaging to detect recurrence before it becomes symptomatic.
Staging prognosis: A very high pre-operative CEA (> 5 ng/mL) in colorectal cancer is associated with poorer prognosis and higher likelihood of metastasis.
CEA limitations
- It has low sensitivity for early-stage colorectal cancer — approximately 30–40% of Stage I–II patients will have normal CEA despite active tumours
- It cannot localise where cancer is — an elevated level requires imaging to find the source
- It is not useful for screening in the general population
Integrative considerations CEBM Level 4–5
Several natural compounds have been studied for their ability to reduce tumour-derived CEA in the context of adjuvant therapy:
- Curcumin — shown in some studies to downregulate CEA expression in colorectal cancer cell lines
- Green tea (EGCG) — associated with lower colorectal cancer risk in population studies
- Sulforaphane (from broccoli) — epigenetic modulation of cancer cell expression patterns
These are preclinical/observational findings, not substitutes for oncological monitoring, but may be relevant in an integrative protocol discussed with your oncology team.
CA-125 — Cancer Antigen 125
What is CA-125?
CA-125 (also called MUC16) is a protein found on the surface of many ovarian cancer cells and some normal tissue. It is the most widely used biomarker for epithelial ovarian cancer — the most common and deadliest form of ovarian cancer.
What cancers is CA-125 used for?
- Epithelial ovarian cancer (primary use)
- Fallopian tube cancer
- Primary peritoneal cancer
- Endometrial cancer
- Cervical adenocarcinoma
- Uterine cancer
- In men: sometimes elevated in pancreatic and lung cancer
Normal reference ranges
| Interpretation | CA-125 Level |
|---|---|
| Normal (pre-menopausal) | < 35 U/mL |
| Normal (post-menopausal) | < 35 U/mL (stricter interpretation applies) |
| Borderline | 35–65 U/mL |
| Elevated — warrants investigation | > 65 U/mL |
| Highly elevated — strong concern | > 200 U/mL |
Post-menopausal women with elevated CA-125 carry a higher risk of malignancy than pre-menopausal women with the same level — the RMI (Risk of Malignancy Index) score takes this into account alongside ultrasound findings.
Non-cancerous causes of elevated CA-125
Like CEA, CA-125 is not specific to cancer:
- Endometriosis — can cause very high CA-125 (sometimes > 100 U/mL)
- Uterine fibroids
- Pelvic inflammatory disease
- Peritonitis
- Liver disease
- Heart failure
- Kidney disease
- Normal menstruation (CA-125 fluctuates with the cycle)
- First trimester pregnancy
This is why CA-125 alone is not sufficient for ovarian cancer screening — particularly in pre-menopausal women.
How CA-125 is used clinically
Diagnosis support: Used alongside transvaginal ultrasound and the HE4 (Human Epididymis Protein 4) marker. The ROMA algorithm (Risk of Ovarian Malignancy Algorithm) combines CA-125 and HE4 with menopausal status to calculate malignancy risk — this outperforms CA-125 alone.
Treatment monitoring: Rising CA-125 during chemotherapy (typically carboplatin + paclitaxel) suggests resistance; falling levels suggest response. A 50% reduction within three cycles is a positive prognostic indicator.
Recurrence detection: After remission, CA-125 is checked every 3 months. The CALYPSO and ICON3 trials showed that rising CA-125 predicts clinical recurrence by 2–5 months on average — but importantly, early treatment triggered by CA-125 alone (versus waiting for symptoms) does not improve overall survival in ovarian cancer. This remains controversial.
The OVA1 and Overa tests are multivariate assays approved by the FDA that combine CA-125 with other serum proteins (transferrin, apolipoprotein A1, transthyretin, beta-2 microglobulin) to improve discrimination between benign and malignant pelvic masses.
CA-125 limitations
- Cannot distinguish between ovarian and other pelvic cancers
- Falsely elevated in many benign gynaecological conditions
- Approximately 20% of epithelial ovarian cancers — particularly the mucinous subtype — are CA-125 negative even at advanced stages
- Not validated as a population screening tool
The ROCA test — updated evidence CEBM Level 1b
The Risk of Ovarian Cancer Algorithm (ROCA) monitors the rate of change in CA-125 over time rather than using a fixed threshold. In the landmark UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, over 200,000 postmenopausal women), ROCA-based multimodal screening detected significantly more low-volume, early-stage cancers than no screening. However, after a median 11.1 years of follow-up, there was no statistically significant reduction in ovarian cancer mortality in either the ROCA or ultrasound screening arms compared with no screening (0.32% ROCA vs. 0.35% control; hazard ratio 0.89, 95% CI 0.74–1.08). Exploratory analyses suggested a possible delayed mortality benefit emerging beyond 10 years, but this has not been confirmed. This is precisely why no major guideline body — including USPSTF — recommends CA-125/ROCA screening in average-risk women. ROCA remains used in some high-risk surveillance programmes (e.g., BRCA carriers), where the calculus of benefit versus harm differs.
Integrative considerations CEBM Level 3–5
- Vitamin D deficiency is associated with higher ovarian cancer incidence and poorer prognosis in observational studies. Optimising vitamin D (target 25-OH-D > 60 ng/mL) is widely recommended in integrative oncology
- IP6 (inositol hexaphosphate) has been studied as an adjunct in ovarian cancer protocols
- Berberine — preclinical evidence for PI3K/AKT pathway inhibition relevant to ovarian cancer
PSA — Prostate-Specific Antigen
What is PSA?
PSA is a serine protease enzyme produced almost exclusively by the prostate gland — both healthy and malignant prostate tissue produces it. It is the most widely used cancer biomarker in the world and one of the most controversial.
Normal PSA ranges (by age)
| Age Group | Suggested Upper Normal |
|---|---|
| 40–49 years | 2.5 ng/mL |
| 50–59 years | 3.5 ng/mL |
| 60–69 years | 4.5 ng/mL |
| 70–79 years | 6.5 ng/mL |
Most labs use a universal cut-off of 4.0 ng/mL, but this misses cancers in younger men (who should have lower levels) and over-triggers biopsy in older men.
PSA density and PSA velocity
PSA density = PSA level ÷ prostate volume (measured by ultrasound). A density > 0.15 ng/mL/cc increases suspicion for cancer versus benign prostatic hyperplasia (BPH).
PSA velocity = the rate of PSA rise over time. An annual rise > 0.75 ng/mL/year (if PSA > 4) or > 0.35 ng/mL/year (if PSA < 4) raises concern for cancer, though this remains debated.
PSA doubling time (PSADT) — used in active surveillance. A doubling time < 3 years suggests aggressive disease requiring intervention.
Free vs. total PSA
PSA circulates in two forms:
- Bound PSA — attached to proteins; associated with cancer
- Free PSA — unbound; higher proportions are more common in BPH
% free PSA = (free PSA ÷ total PSA) × 100
A free PSA percentage < 10% significantly increases the probability of cancer (approximately 56% probability). > 25% free PSA suggests BPH. This test helps reduce unnecessary biopsies when total PSA is in the 4–10 ng/mL "grey zone."
Non-cancerous causes of elevated PSA
- Benign prostatic hyperplasia (BPH) — the most common cause of elevated PSA
- Prostatitis (infection/inflammation) — can cause dramatic temporary rises
- Recent ejaculation (within 24–48 hours)
- Vigorous cycling or perineal trauma
- Recent prostate biopsy or TURP (can elevate PSA for weeks)
- Urinary tract infection
- Certain medications (testosterone; finasteride artificially lowers PSA — the PSA should be doubled for interpretation in men on finasteride)
The PSA screening controversy — and 2026's shifting guidance CEBM Level 1
The two landmark PSA screening trials tell different stories:
PLCO trial (US) — found no survival benefit from PSA screening versus usual care. However, this trial was heavily criticised for contamination (many control patients received PSA testing anyway).
ERSPC trial (European) — found a 21% reduction in prostate cancer death with PSA screening, but at the cost of significant overdiagnosis and overtreatment of low-grade, clinically insignificant cancers.
Guideline bodies do not fully agree as of 2026
- AUA/SUO (2026 update): now offers a stronger, structured recommendation — clinicians should offer regular PSA screening every 2 to 4 years to men aged 50 to 69 (Strong Recommendation), with re-screening interval or discontinuation personalised thereafter.
- USPSTF (last formally updated 2018): still frames screening for ages 55–69 as an individual, shared decision-making choice, and recommends against screening at age 70+.
- ESMO (2026 update): recommends against population-based PSA screening, citing overdiagnosis and overtreatment, while supporting individualised, risk-adapted baseline testing for higher-risk men.
In short: the pendulum in 2026 is swinging toward more structured, protocolised screening in US urology guidance, while European oncology guidance remains more cautious. Discuss which framework your clinician is using.
High-risk men (Black/African descent, family history of prostate/breast/ovarian cancer, known BRCA2 mutation) benefit most from earlier and more frequent screening under nearly all frameworks. Screening before age 40 is not recommended by any major body.
The 4Kscore and Prostate Health Index (PHI)
These validated multimarker tests outperform PSA alone:
4Kscore combines total PSA, free PSA, intact PSA, and human kallikrein 2 (hK2) with age, DRE result, and prior biopsy status to calculate the probability of high-grade (Gleason ≥ 7) prostate cancer. This markedly reduces unnecessary biopsies.
PHI (Prostate Health Index) = ([-2]proPSA / free PSA) × √total PSA. An elevated PHI (> 55) is associated with higher risk of aggressive cancer. FDA-approved; available in many countries including Malaysia.
Active surveillance and PSA
For men with low-risk prostate cancer, active surveillance (AS) avoids immediate treatment while monitoring progression. PSA monitoring is the cornerstone of AS, with regular biopsies and increasingly, multiparametric MRI (mpMRI). A rising PSA on AS is not an automatic trigger to treat — the rate of rise (doubling time) and confirmatory biopsy matter.
Integrative considerations for PSA management CEBM Level 2–4, mixed
- Lycopene (tomatoes, especially cooked) — associated with lower PSA and reduced prostate cancer risk in multiple studies. Dose typically 10–30 mg/day
- Pomegranate extract — shown in a phase II trial to extend PSA doubling time in men with recurrent prostate cancer after surgery/radiation
- Green tea catechins — a randomised trial (Bettuzzi et al.) showed that EGCG supplementation significantly reduced progression from high-grade PIN to prostate cancer
- Modified citrus pectin — preliminary evidence for slowing PSA velocity
- Selenium — mixed evidence; the SELECT trial showed no benefit from supplementation in unselected men, but selenium status at baseline matters
- Curcumin — androgen receptor modulation; synergy with androgen deprivation therapy being studied
- Diet: a whole-food plant-rich diet low in saturated animal fat is consistently associated with slower prostate cancer progression. The MEAL (Men's Eating and Living) trial showed significant slowing of PSA rise in men adopting a plant-based diet
CTC — Circulating Tumour Cells
What are CTCs?
Circulating tumour cells are intact cancer cells that detach from a primary tumour (or metastasis) and travel through the bloodstream. Detecting even a few of these rare cells provides a "liquid biopsy" — a non-invasive window into tumour biology.
CTCs were first described in 1869 by Thomas Ashworth, who observed cells resembling cancer cells in the blood of a man who had died from cancer. Reliable clinical assays only became available in the 2000s.
How CTC testing works
CellSearch system (Menarini) is the most established and most widely validated CTC platform, cleared by the FDA for prognostic use in metastatic breast (2004), colorectal (2007), and prostate (2008) cancer. It uses immunomagnetic enrichment to isolate cells expressing the epithelial marker EpCAM, then counts cells expressing cytokeratins 8, 18, and 19 while being negative for the white blood cell marker CD45.
Blood volume tested: typically 7.5 mL.
Note on platform landscape: CellSearch is no longer the only FDA-cleared CTC technology. The Parsortix PC1 System (ANGLE plc) received FDA clearance in 2022 for capturing and harvesting CTCs from the blood of metastatic breast cancer patients, enabling downstream, user-validated molecular analysis — a narrower clearance (capture/harvest) than CellSearch's enumeration-and-prognosis claim, but a meaningful addition to the field.
Newer platforms use microfluidic chips, size-based filtration, or functional assays to capture CTCs regardless of EpCAM expression — important because aggressive, epithelial-to-mesenchymal transition (EMT) cancer cells downregulate EpCAM and are missed by CellSearch.
CTC reference thresholds (CellSearch)
| Cancer Type | Unfavourable Count |
|---|---|
| Metastatic breast cancer | ≥ 5 CTCs per 7.5 mL blood |
| Metastatic colorectal cancer | ≥ 3 CTCs per 7.5 mL blood |
| Metastatic prostate cancer | ≥ 5 CTCs per 7.5 mL blood |
In healthy individuals, CTCs should be undetectable (0 per 7.5 mL).
What CTC counts tell us
Prognosis: In metastatic breast, colorectal, and prostate cancer, CTC count is one of the strongest independent prognostic factors. Patients with ≥ 5 CTCs (breast, prostate) have significantly shorter progression-free and overall survival than those with < 5.
Treatment monitoring: Converting from an unfavourable to a favourable CTC count (e.g. ≥ 5 dropping to < 5) within the first cycle of a new treatment predicts improved survival — sometimes weeks before imaging shows a response. This is particularly valuable in metastatic breast and prostate cancer.
Early recurrence detection: Rising CTCs after remission may signal recurrence before imaging or symptoms. Research is ongoing; this is not yet standard practice.
Treatment resistance: Molecular analysis of captured CTCs can identify resistance mutations (e.g. androgen receptor splice variant 7 / AR-V7 in castration-resistant prostate cancer — men with AR-V7-positive CTCs respond poorly to enzalutamide and abiraterone but may respond to taxane chemotherapy).
CTC limitations
- Currently validated only for metastatic cancers — not useful for early-stage screening in most settings
- EpCAM-based platforms miss EMT-type cells that may represent the most dangerous, stem-like cancer cell population
- Rare cell counts mean results can be variable between draws
- Not yet standard of care in most oncology guidelines outside of research centres
- High cost and limited availability, particularly in Southeast Asia
The RGCC test
The RGCC (Research Genetic Cancer Centre) offers a broader liquid biopsy panel (Oncocount, Onctrace, Oncotrace+) that combines CTC enumeration with molecular profiling, testing CTCs against a panel of chemotherapy drugs and natural compounds to guide treatment selection. While not FDA-approved and limited by regulatory-grade clinical validation, it is used in integrative oncology settings including some Malaysian and Singapore clinics. Patients should understand the evidence base before pursuing this test.
Circulating tumour DNA (ctDNA) — the next frontier
While not CTCs, ctDNA deserves mention. ctDNA consists of fragments of tumour-derived DNA shed into the bloodstream. Tests like Guardant360, FoundationOne Liquid CDx, and GRAIL's Galleri multi-cancer early detection (MCED) test analyse ctDNA for cancer-associated mutations and methylation patterns — see our full 2026 ASCO ctDNA guidelines guide and the Galleri vs. Cancerguard comparison.
Comparing the Four Biomarkers: A Quick Reference
| Feature | CEA | CA-125 | PSA | CTC |
|---|---|---|---|---|
| Primary cancer | Colorectal | Ovarian | Prostate | Multiple (metastatic) |
| FDA-approved screening? | No | No | Conditional | No (monitoring only) |
| Screening utility | Low | Low | Contested (see 2026 guideline split) | Research stage |
| Monitoring utility | High | High | High | High (metastatic) |
| Recurrence detection | Yes | Yes | Yes | Emerging |
| Non-cancer elevation | Common | Common | Common | Rare |
| Actionable results | Yes (colorectal) | Yes (ovarian) | Yes (prostate) | Yes (metastatic) |
Understanding Your Results: A Patient's Checklist
If your doctor has ordered one of these tests, here are the most important questions to ask:
1. Why is this test being ordered? Is it for screening, diagnosis, treatment monitoring, or recurrence surveillance? The clinical context completely changes how to interpret the result.
2. What is the trend, not just the number? A single result rarely tells the full story. A CEA of 8 that was previously 3 is more concerning than a stable CEA of 8 that has been unchanged for two years.
3. What other tests are needed alongside this result? An elevated CA-125 alone is insufficient — it must be combined with ultrasound and clinical history. An elevated PSA requires free PSA, ideally PHI or 4Kscore, and possibly mpMRI before biopsy.
4. Have benign causes been excluded? Before pursuing invasive investigations, ensure that common non-cancerous causes (infection, inflammation, smoking, menstruation) have been considered.
5. Is this result changing my management? Biomarker testing should drive decisions. If your oncologist is monitoring CEA after colorectal cancer surgery, agree in advance what threshold or trend will trigger the next step.
The Future of Biomarker Testing
The field is moving rapidly toward multimarker panels and AI-assisted interpretation:
Multi-cancer early detection (MCED) — updated with 2026 ASCO data CEBM Level 1b (RCT)
GRAIL's Galleri test aims to replace single-marker screening with a pan-cancer liquid biopsy that analyses methylation patterns in cell-free DNA. The NHS-Galleri trial — the first and only randomised controlled trial of an MCED test, enrolling 142,250 participants aged 50–77 across three annual screening rounds — reported full results at the 2026 ASCO Annual Meeting. The trial did not meet its primary endpoint of reducing combined Stage III/IV cancer diagnoses in aggregate, but did show a reduction in Stage IV diagnoses specifically beyond the first (prevalent) screening round, and a 16% increase in Stage I–II diagnoses after three rounds of annual screening across the 12 prespecified cancer types, including cancers typically caught late such as ovarian, oesophageal, pancreatic, and liver cancer. Reported performance: specificity 99.55%, positive predictive value 52%, sensitivity 54.7% (12 prespecified cancers) / 30.7% (all cancers), negative predictive value 98.92%, and site-of-origin prediction accuracy of 87% (top prediction) / 92.5% (top two predictions). Separately, GRAIL's US-based PATHFINDER 2 study (~35,000 participants) reported higher episode sensitivity (69.8% for the 12 highest-mortality cancers, 39.3% across all cancers) and a specificity of 99.6%. It remains unknown whether all cancers detected this way would ever have become clinically significant, or whether earlier detection with Galleri improves overall survival — that data will take years longer to mature. As of 2026, Galleri is a laboratory-developed test (not FDA-approved or cleared) available commercially in the US; it is not a replacement for guideline-recommended screening. For a full head-to-head with the newer Cancerguard test, see our dedicated MCED comparison guide.
- Methylation-based tests can identify the tissue of origin of ctDNA, pointing to where a cancer is located even before imaging
- Proteomics panels combine dozens of proteins simultaneously; EarlyCDT (Oncimmune) uses autoantibody panels for lung cancer early detection
- Tumour microenvironment biomarkers — PD-L1 expression, tumour mutational burden (TMB), microsatellite instability (MSI) — are used to predict immunotherapy response
Precision oncology is shifting away from "one marker, one cancer" toward integrated molecular portraits of individual tumours.
Using AI to Help Interpret Your Biomarker Results
AI assistants can be a genuinely useful second pass for organising and understanding lab reports — but none of them can examine you, order the confirmatory tests you need, or take responsibility for a diagnosis. Used well, they can help you prepare better questions for your actual appointment.
| Tool | Where it tends to help most |
|---|---|
| Claude | Uploading a PDF lab report and asking it to plot your CEA or CA-125 trend over time, flag which values fall outside your lab's reference range, and draft a written list of questions for your oncologist |
| ChatGPT | Plain-language explanations of unfamiliar terms on a pathology or lab report, and role-playing a conversation to rehearse what to ask at your next visit |
| Gemini | Cross-referencing a result against recent, searchable medical literature or guideline pages when you want pointers to primary sources |
| Perplexity | Quickly pulling together citations from multiple recent sources when you want to fact-check a claim you read online about a biomarker or test |
A prompt worth trying
"Here is my CEA lab history: [dates and values]. I have a history of [condition]. Explain the trend in plain language, note anything that falls outside typical reference ranges, and list three specific questions I should ask my oncologist at my next appointment. Do not suggest a diagnosis."
None of these tools replace your oncologist or a qualified physician. AI outputs can be wrong, outdated, or miss context only your treating team has. Always bring AI-generated questions to a real clinical appointment rather than acting on AI-generated conclusions alone.
Frequently Asked Questions
What is considered a normal CEA level?
In non-smokers, normal CEA is generally below 2.5 ng/mL; in smokers, up to 5.0 ng/mL is considered normal because smoking itself raises baseline CEA. Levels above 10 ng/mL are more suspicious for malignancy, but reference ranges vary by lab and CEA is not diagnostic on its own.
Can CA-125 be elevated without cancer?
Yes. CA-125 commonly rises with endometriosis, uterine fibroids, pelvic inflammatory disease, liver disease, heart failure, and even normal menstruation or early pregnancy. This is why CA-125 alone is not recommended for ovarian cancer screening, particularly in pre-menopausal women.
Is PSA screening still recommended in 2026?
Guidance varies by organisation. The 2026 AUA/SUO guideline supports regular PSA screening every 2 to 4 years for men aged 50 to 69, USPSTF continues to recommend individualised shared decision-making for ages 55 to 69 and against screening for age 70+, and ESMO's 2026 update advises against population-wide PSA screening. Discuss your personal risk factors with your physician.
What does a CTC count of 5 or more mean?
In metastatic breast and prostate cancer, a CellSearch CTC count of 5 or more per 7.5 mL of blood is classified as "unfavourable" and is associated with shorter progression-free and overall survival. In metastatic colorectal cancer, the unfavourable threshold is 3 or more CTCs.
Can a biomarker test alone diagnose cancer?
No. Biomarkers such as CEA, CA-125, and PSA are tools that raise or lower suspicion; they cannot confirm a cancer diagnosis on their own. Elevated results require correlation with imaging, clinical history, and in most cases tissue biopsy before a diagnosis can be made.
How often is CEA checked after colorectal cancer treatment?
Standard practice is to monitor CEA every 3 to 6 months for the first 2 years after curative treatment, then annually, with a sustained rise prompting imaging to investigate possible recurrence.
Is the Galleri multi-cancer test the same as CEA, CA-125, or PSA testing?
No. Galleri is a methylation-based liquid biopsy that screens for signals from more than 50 cancer types in one blood draw, while CEA, CA-125, and PSA are single-marker protein tests tied to specific cancer types. Galleri is a laboratory-developed test, not yet FDA-approved, and is intended to complement — not replace — guideline-recommended screening such as mammography, colonoscopy, or PSA testing.
Is a blood test the same as a screening test for colorectal cancer?
Not necessarily. CEA is a monitoring marker used after a colorectal cancer diagnosis, not a screening test. Separately, the American Cancer Society's 2026 guideline update added a different blood-based ctDNA test (Shield) as a non-preferred colorectal cancer screening option for people who decline colonoscopy or stool-based testing.
Key Takeaways
- No single biomarker is diagnostic of cancer on its own. All require clinical correlation, imaging, and often tissue biopsy.
- CEA is most useful for monitoring colorectal cancer — not screening. Smokers have higher baseline levels. It is not the same as the newer blood-based CRC screening test (Shield) added to ACS's 2026 guideline.
- CA-125 is best used alongside HE4 and ultrasound in peri- and post-menopausal women. ROCA improves early detection but has not shown a statistically significant mortality benefit in average-risk women after 11+ years of follow-up.
- PSA screening guidance is not uniform in 2026. AUA/SUO now supports structured regular screening (ages 50–69); USPSTF and ESMO remain more conservative. Free PSA, PHI, or 4Kscore reduce unnecessary biopsies. Men on finasteride must double their PSA for correct interpretation.
- CTC testing is validated for monitoring metastatic breast, colorectal, and prostate cancer. CellSearch remains the primary platform, but Parsortix PC1 also holds FDA clearance for CTC capture. CTC is not a screening tool but provides real-time prognostic information.
- Trends matter more than single values. Consistent rising trends are more clinically meaningful than single elevated readings.
- Integrative approaches (lycopene, EGCG, curcumin, vitamin D) may complement conventional monitoring but do not replace it.
References and Further Reading
- Duffy MJ. Tumour markers in clinical practice: a review focusing on common solid cancers. Medical Oncology. 2021.
- Diamandis EP. CEA, CA-125, PSA: biomarkers in clinical practice. Critical Reviews in Clinical Laboratory Sciences. 2019.
- Bast RC Jr et al. The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer. 2009.
- Menon U, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182–2193.
- Loeb S, Catalona WJ. The prostate health index: a new test for the detection of prostate cancer. Therapeutic Advances in Urology. 2014.
- American Urological Association / Society of Urologic Oncology. Early Detection of Prostate Cancer Guideline, 2026 update.
- Cristofanilli M et al. Circulating tumour cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine. 2004.
- Wolf AMD, Hoffman RM, Walter LC, et al. Colorectal cancer screening: An update to the American Cancer Society guideline, 2026. CA: A Cancer Journal for Clinicians. 2026.
- Swanton C, et al. NHS-Galleri: primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection test in population screening. Presented at the ASCO Annual Meeting, 2026.
- Klein EA et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology. 2021.
- Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015.
Related
- Genetics, Genomics and Precision Oncology (2026): The Ultimate Guide to Precision Oncology, Targeted Therapy, and the Future of Cancer Treatment.
- 2026 ASCO Guidelines on ctDNA Testing: A Patient's Guide to Liquid Biopsies
- MCED Tests in 2026: Galleri vs Cancerguard and the Future of Early Cancer Detection
This article is for educational purposes only. It does not constitute medical advice. Always discuss biomarker testing decisions with a qualified oncologist or physician. If you are in Malaysia or Singapore, the Find a Doctor section can help you locate an integrative oncology specialist.
© 2026 OneDayMD.com / The Medical Advisor. All rights reserved.
.png)
.png)
Comments
Post a Comment